A new study published in the journal Nature describes a highly engineered metabolic drug that combines five distinct therapeutic activities into a single molecule — and in preclinical mouse studies, it outperformed both Ozempic and dual incretin-based therapies resembling Mounjaro. The molecule, called GLP-1-GIP-lanifibranor (GLP-1-GIP-Lani), was developed by an international consortium of researchers and represents one of the most sophisticated examples yet of rationally designed multi-target metabolic pharmacology.
Rather than acting on a single pathway, the drug simultaneously targets five biologically interconnected systems involved in appetite suppression, insulin sensitivity, glucose regulation, inflammation, and lipid metabolism. The findings suggest that the next generation of obesity therapeutics may not simply involve stronger appetite suppressants, but rather highly coordinated molecular systems capable of rewiring multiple metabolic pathways at once.
The Problem With One Target at a Time
Modern obesity pharmacology has been transformed by incretin-based drugs that mimic naturally occurring gut hormones released after food intake. These hormones communicate with the brain and pancreas to regulate appetite, insulin secretion, and energy balance. Semaglutide activates the GLP-1 receptor alone, whereas tirzepatide targets both GLP-1 and GIP receptors simultaneously, producing greater weight reduction and improved glycemic control compared with earlier therapies.
Despite these advances, researchers have continued exploring whether additional metabolic pathways could be engaged simultaneously to further improve therapeutic outcomes. One particularly important family of targets is the peroxisome proliferator-activated receptors (PPARs), which include PPARα, PPARγ, and PPARδ. These nuclear receptors regulate gene expression programs involved in fatty acid metabolism, glucose handling, inflammation, and cellular energy utilization.
Historically, PPAR-targeting drugs have shown mixed clinical success. Some improved insulin sensitivity and lipid metabolism but produced undesirable side effects including fluid retention, anemia, cardiovascular complications, and weight gain. Lanifibranor, a pan-PPAR agonist currently being investigated for metabolic dysfunction-associated steatohepatitis (MASH), demonstrated meaningful improvements in liver fibrosis and inflammation in clinical studies, but it also retained several of these classical PPAR-associated toxicities.
The major challenge therefore became whether the beneficial metabolic effects of PPAR activation could be selectively harnessed without exposing the entire body to systemic toxicity. The new study approached this problem using an elegant receptor-targeted delivery strategy.
A Molecular Trojan Horse
The conceptual breakthrough of the study was not simply combining incretin agonism with PPAR agonism, but engineering both functions into a single targeted molecule. The research team, led by investigators at Helmholtz Munich together with collaborators from Duke University, Yale University, Indiana University, Novo Nordisk, and the University of Copenhagen, exploited the biology of incretin receptors themselves.
GLP-1 and GIP receptors naturally internalize into cells after ligand binding. The investigators reasoned that attaching lanifibranor to a GLP-1/GIP co-agonist backbone would allow the PPAR agonist to be selectively transported into cells expressing incretin receptors, including pancreatic beta cells, adipocytes, and certain neuronal populations.
The resulting molecule therefore acts as a quintuple agonist:
- GLP-1 receptor agonist
- GIP receptor agonist
- PPARα agonist
- PPARγ agonist
- PPARδ agonist
This receptor-mediated delivery mechanism effectively transformed incretin receptors into molecular transport systems capable of selectively delivering a potent nuclear receptor agonist into metabolically relevant cells while avoiding widespread systemic exposure.
One of the most remarkable findings was that lanifibranor could be used at doses nearly 6,900-fold lower than those required when administered as a standalone drug. This dramatic dose reduction likely underlies the improved safety profile observed in the study.
In the Lab: Selective Intracellular PPAR Activation
In cultured cells expressing GLP-1 or GIP receptors, the conjugated molecule retained full incretin signaling activity. It produced comparable cAMP responses and insulin secretion relative to unconjugated GLP-1/GIP agonists, indicating that attaching lanifibranor did not compromise incretin receptor function.
The PPAR biology, however, revealed the real sophistication of the design. In cells expressing both incretin receptors and PPARs, the drug robustly activated expression of PDK4, a canonical PPAR-responsive gene. Yet in cells lacking incretin receptors, essentially no PPAR activation occurred.
In other words, the PPAR agonist payload remained pharmacologically silent unless the incretin receptor-mediated internalization mechanism delivered it into the cell. This selective intracellular activation demonstrated that the targeting strategy worked exactly as intended.
In Obese Mice: Superior Metabolic Effects
The in vivo studies used multiple obesity and diabetes mouse models, including diet-induced obese mice and genetically obese db/db mice. Across essentially every major metabolic endpoint examined, GLP-1-GIP-Lani outperformed comparator therapies.
Compared with semaglutide and GLP-1/GIP co-agonism alone, the quintuple agonist produced:
- Greater body weight reduction
- Lower food intake
- Reduced fat mass
- Improved glucose tolerance
- Lower fasting glucose
- Enhanced insulin sensitivity
Importantly, lean body mass was relatively preserved despite substantial fat loss.
Hyperinsulinemic-euglycemic clamp studies further demonstrated significantly improved insulin sensitivity. The drug also suppressed endogenous hepatic glucose production more effectively than incretin agonism alone, accompanied by reduced expression of gluconeogenic enzymes including Pcx and Pepck1.
A particularly important experiment demonstrated that the glucose-lowering effects were not merely secondary to weight loss. When researchers weight-matched mice receiving GLP-1-GIP-Lani against mice receiving GLP-1/GIP plus calorie restriction, the GLP-1-GIP-Lani-treated mice still showed superior glycemic control. This suggests the molecule exerts partially weight-independent metabolic effects.
In the notoriously treatment-resistant db/db mouse model, the drug completely prevented body weight gain — a striking observation given the relative resistance of this model to existing incretin therapies.
Dissecting the Mechanism
Because the drug simultaneously activates five targets, the investigators used genetic and pharmacologic approaches to determine which components contributed to different biological effects.
Loss of GLP-1 receptor signaling in glutamatergic neurons partially impaired weight loss, while deletion of GIP receptor signaling similarly reduced efficacy. When both incretin receptors were absent, the metabolic effects disappeared entirely, confirming that incretin receptor engagement is essential for the molecule’s activity.
The glucose-lowering effect, however, appeared especially dependent on PPARδ signaling. Pharmacologic inhibition of PPARδ abolished the enhanced glycemic improvement without significantly affecting body weight reduction. This suggests that incretin agonism primarily drives appetite suppression and weight loss, whereas PPARδ signaling contributes strongly to improved glucose homeostasis and insulin sensitivity.
Safety: Avoiding Classical PPAR Toxicity
One of the most significant findings was what the drug failed to induce. Traditional systemic PPAR agonists frequently cause edema, anemia, adipogenesis, and weight gain. Yet chronic GLP-1-GIP-Lani treatment produced none of these classical toxicities in the mouse studies.
The investigators observed:
- No anemia
- No fluid retention
- No increase in total body fluid
- No pathological tissue changes
- No abnormal adipocyte differentiation
Remarkably, the molecule retained beneficial glucose uptake effects in adipocytes without triggering the adipogenic differentiation typically associated with PPARγ activation.
Cardiovascular parameters also improved substantially. Relative to GLP-1/GIP therapy alone, the quintuple agonist reduced cardiac hypertrophy and improved multiple indices of cardiac function, including ejection fraction, stroke volume, and cardiac output.
Importantly, in lean healthy mice the drug produced essentially no metabolic disturbance, suggesting preferential activity within metabolically dysregulated states rather than indiscriminate metabolic suppression.
The Brain Dimension
The study also explored how the drug affects central nervous system pathways involved in appetite regulation. Neither GLP-1-GIP nor GLP-1-GIP-Lani crossed the blood-brain barrier in vitro, indicating that their central effects are likely mediated indirectly through accessible brain regions or peripheral signaling pathways.
Despite similar activation of classical satiety-associated brain regions, the quintuple agonist produced dramatically different proteomic signatures in both the hypothalamus and brainstem compared with incretin agonism alone. GLP-1-GIP-Lani regulated hundreds of proteins involved in nuclear processes, RNA regulation, chromosome organization, and transcriptional control — molecular signatures highly consistent with intracellular PPAR activity.
Most notably, the molecule produced stronger activation of POMC neurons, the canonical appetite-suppressing neurons within the arcuate nucleus. Enhanced activation of these neurons likely contributes substantially to the superior weight reduction observed in treated animals.
Context and Caveats
The study remains entirely preclinical, and several important limitations remain. All experiments were conducted in male mice, leaving unanswered questions regarding sex-specific responses. The precise tissue-specific contributions of each PPAR subtype also remain incompletely understood due to technical limitations associated with receptor knockout models.
Most importantly, obesity drug development has historically been filled with compounds that produced impressive rodent data but failed in humans. Mouse metabolism and human metabolism are not identical, and long-term safety in humans remains unknown.
Nevertheless, the conceptual framework demonstrated by this study is highly significant. The work shows that incretin receptors can function not only as therapeutic targets, but also as selective intracellular delivery vehicles capable of transporting otherwise toxic metabolic regulators into highly specific cellular populations.
What Comes Next
GLP-1-GIP-Lani remains an early-stage preclinical candidate, and substantial hurdles remain before human translation becomes possible. Manufacturing, pharmacokinetics, large-animal toxicology, and eventual clinical trials will all determine whether the compound can progress further.
Still, the study represents an important milestone in the evolution of metabolic therapeutics. Rather than viewing obesity and diabetes through the lens of single-target pharmacology, the field increasingly appears to be moving toward rationally engineered polypharmacology — therapeutics designed to coordinate multiple biological systems simultaneously while minimizing toxicity through precision delivery mechanisms.
Whether GLP-1-GIP-Lani itself eventually reaches patients remains uncertain. But the principle demonstrated by this work — that multi-receptor targeting combined with built-in delivery specificity can produce synergistic metabolic effects while avoiding classical toxicities — is likely to influence the next generation of obesity and diabetes drug development for years to come.
Reference
Liskiewicz, D., Novikoff, A., Khalil, A. et al. GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Nature (2026). https://doi.org/10.1038/s41586-026-10427-5
Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI) or Google Gemini.
Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.
3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.
3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
